Skip to main content
Equibles
INTS logo

INTS · Intensity Therapeutics, Inc.

Track INTS — free

Use INTS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INTS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.43 +0.06 (+1.78%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the cash and cash equivalents as of June 30, 2026, the Company's ability to continue its operations thereafter is dependent on obtaining additional capital, which is not within the Company's control. As a result, the Company believes there is substantial doubt about its ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$12.41M
Shares
3.26M
Volume · Oct 1 7030 Avg daily vol (3M) 30.74K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.37 Open$3.40 Day$3.28–3.46 52W close$3.37–33.00 Avg vol 30d26K Short int31K · 1.0% float · 2.6d Short vol61% Last earningsAug 11, 2026 DataJun 2023–Sep 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026
Q2 2026 earnings call transcript
call held Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$11.16M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+258.6%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.0%
Latest settlement · 2.6 days to cover
View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 11, 2026
Q2 FY26

TL;DR. Intensity Therapeutics (INTS) restarted enrollment in the Phase 3 INVINCIBLE-3 sarcoma study using an FDA-reviewed amended protocol and resumed treatment in the Phase 2 INVINCIBLE-4 TNBC study, while reporting a Q2 net loss of $3.0 million and $9.5 million in cash that management says is insufficient to fully open all sites without additional capital.

Bullish
  • + Initiated activities to resume enrollment in the Phase 3 INVINCIBLE-3 soft tissue sarcoma study in select U.S. sites under an FDA-reviewed amended protocol.
  • + Restarted patient treatment in the Phase 2 INVINCIBLE-4 TNBC study, opened first French site, and targets complete enrollment by end of 2027.
  • + Preliminary INVINCIBLE-4 data showed 71% pCR with INT230-6 vs 42% pCR on SOC alone and a 44% reduction in grade 3 adverse events.
  • + Established a $60 million ATM facility and raised $1.6 million net in Q2 2026 plus $1.3 million subsequent to quarter-end.
Bearish
  • − Q2 2026 net loss widened to $3.0 million from $2.5 million in Q2 2025, driven by higher R&D and bonus accruals.
  • − Management estimates $30 million is needed over the next several years to complete INVINCIBLE-3, and current funding is only sufficient to incrementally open sites.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.53
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −44%
below
Price vs 50-day avg −19%
below
RSI (14) 29
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −17%
trailing
6-month return −40%
trailing
YTD return −67%
this year
Relative strength −52%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow Accumulating
+21% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.96% of float · ▼ -36.0% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
17 holders — mid 3-yr range
Squeeze score 34
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 408%
annualized · 1-yr
Max drawdown −90%
past year
ATR 7.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−44% Bearish
Price vs 50-day avg
−19% Bearish
RSI (14)
29 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow Accumulating
+21% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.96% of float · ▼ -36.0% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
17 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $3 · 0% Range high $33
vs 200-day avg -44% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
INTS
Intensity Therapeutics, Inc.
this stock
$12.41M — — — 1.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +15.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -1.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +553.0% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
17
% held
35.8%
Net QoQ
+988.4K sh
Top holder
Kingsbury Capital Investm…
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Falling
Shares short
31.3K
Days to cover
2.6d
Change
-17.6K sh
View
Short Volume
Short vol %
61%
As of
Sep 30, 2026
Short Total
View
Fails to Deliver
FTD shares
825
Value
$3.3K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
68.2%
Week of
Aug 24, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-11.6M
EPS diluted
$-8.56
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 11, 2026
This year
13
View
Exempt Offerings
Offering
$3.6M
Filed
Dec 5, 2024
View
Earnings & Events
Earnings Calls Upcoming
Next call
Dec 31, 2026
Last call
Sep 11, 2026
View
Investor Relations
Upcoming events
3
View

Performance

5D 20D 120D MTD YTD
INTS -17.8% -17.2% -39.8% -20.0% -67.1%
SPY -0.7% +0.1% +12.2% -0.6% +11.8%
vs SPY -17.1% -17.3% -52.0% -19.4% -79.0%
Key facts CIK 1567264 CUSIP 45828J202 Visit website Investor relations